LifeVantage Corp. Stock Hits New 52-Week Low at USD 7.10

LifeVantage Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 7.10 as of November 3, 2025. This marks a significant decline for the company, which has seen its stock price drop by approximately 32.98% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
Despite the recent downturn, LifeVantage has reported a notable increase in net profit for the first half of the year, reaching USD 5.43 million, a growth of 83.16%. The company also boasts a strong return on equity (ROE) of 28.30%, indicating efficient management. However, its long-term growth has been hindered, with operating profit declining at an annual rate of 5.22% over the last five years.

LifeVantage's market capitalization stands at USD 145 million, and it maintains a dividend yield of 1.84%. The company's debt-to-equity ratio is notably low at -0.53, reflecting a solid financial position. As it navigates these challenges, the stock's performance continues to attract attention within the industry.